GlobeNewsWire
26 Aug 2026, 13:45 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
3 claims · each scored for market impact
FDA briefing documents revealed that Capricor Therapeutics submitted a final statistical analysis plan for its Dermamiocel BLA that was not previously reviewed or agreed upon by the FDA. — Regulatory disagreement or lack of alignment on statistical analysis plans significantly increases the risk of a BLA rejection or a complete response letter (CRL).
-0.80Capricor Therapeutics' stock price fell 64% ($12.70) on July 27, 2026, following the release of the FDA briefing documents. — The massive price drop indicates a severe loss of investor confidence in the company's primary product pipeline.
-0.50A class action lawsuit has been filed against Capricor Therapeutics alleging securities fraud for the period between December 17, 2025, and July 26, 2026. — Litigation introduces additional legal expenses and potential settlement liabilities, though it is secondary to the underlying regulatory failure.
-0.30Continue reading
6 related stories
Top 3 movers · tap to explore
Which stocks this story touches
The company is facing a class action lawsuit following a 64% stock price drop due to FDA briefing document issues.
A class action lawsuit has been filed against the company on behalf of investors.
A class action lawsuit has been filed against the company on behalf of investors.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
4h ago
